Characterization of Plasma Cells in Bone Marrow (BM) for cytogenetic abnormalities is a common genetic test to diagnose and monitor multiple myeloma (MM). Plasma cells in MM patients vary in proportion from <1% up to 100%. Even though Circulating Plasma Cells (CPCs) burden in peripheral blood is reported to be >100-fold lower than in BM, their presence is considered an important prognostic marker in patients with MM, with a less invasive sample collection. However, the time-consuming sample preparation steps and the considerable loss of cells during the process is still a significant challenge. The MARS platform addresses it through an easy method to isolate CD138+ plasma cells from peripheral blood without RBC lysis and density gradient centrifugation.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
We divide cookies into necessary cookies and third-party cookies that relate to functionality, technical issues and the collection of statistical and marketing data. No consent to third-party cookies allows you to continue using the website.
If you are looking for more information, we invite you to read our privacy policy.